Standout Papers
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer (2011)
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study (2003)
- Phase II Trial of Bevacizumab in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study (2007)
Immediate Impact
3 by Nobel laureates 14 from Science/Nature 102 standout
Citing Papers
Transcription–replication conflicts underlie sensitivity to PARP inhibitors
2024 StandoutNature
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
2021 Standout
Works of Benjamin E. Greer being referenced
NCCN Framework for Resource Stratification: A Framework for Providing and Improving Global Quality Oncology Care
2016
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
2003 Standout
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Benjamin E. Greer | 5444 | 2884 | 2331 | 2612 | 115 | 8.6k | |
| Helen Huang | 4678 | 2492 | 2616 | 2821 | 66 | 7.9k | |
| William J. Hoskins | 6766 | 3522 | 4483 | 2699 | 146 | 10.5k | |
| Barbara A. Goff | 5306 | 3269 | 2545 | 2322 | 228 | 9.9k | |
| Larry J. Copeland | 4399 | 2631 | 2869 | 1990 | 207 | 7.5k | |
| Sërgio Pecorelli | 4103 | 3770 | 2081 | 2852 | 177 | 10.3k | |
| Howard D. Homesley | 6302 | 5676 | 2881 | 2477 | 173 | 11.0k | |
| Robert C. Knapp | 4473 | 1520 | 1528 | 1528 | 131 | 8.1k | |
| John T. Soper | 3471 | 3479 | 1436 | 1909 | 188 | 8.1k | |
| Rebecca N. Baergen | 3074 | 3057 | 2350 | 1349 | 125 | 7.8k | |
| Costantino Mangioni | 3859 | 4187 | 1979 | 1811 | 173 | 8.0k |
All Works
Loading papers...